Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best affordable biotech stocks to invest in now. On September 12, UBS analyst Ashwani Verma maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $50.00.
Harmony Biosciences Holdings, Inc. reported its fiscal Q2 2025 results on August 5, with its WAKIX franchise continually delivering strong growth with net revenue of $200.5 million for the quarter, up 16% year-over-year.
The company also announced the initiation of next-generation Pitolisant HD Phase 3 registration trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025, with both indications targeted for PDUFA in 2028.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders.
Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
